GSK to double R&D staff in China
GlaxoSmithKline (GSK) which currently has 170 R&D staff in China has plans to boost up its staff to 350 by the end of 2009. According to Carol Zhu,
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
These new data for LifeCycle Pharma (LCP)-Tacro, a once daily immunosuppression drug to prevent rejection after organ transplantation, demonstrated that LCP-Tacro tablets also have a potential best-in-class profile